21st August, 2023 Researchers from the University of Glasgow, UK are part of a cross-Europe project which is aiming to develop a revolutionary new method of treating a wide range of neurological disorders. The Wireless Deep Brain Stimulation Through Engineered Multifunctional Nanomaterials project, or BRAINSTORM, is setting out to develop tiny injectable magnets which could…
Category: Neurology News
SPRAVATO® for adults with treatment-resistant major depressive disorder
Findings presented at Royal College of Psychiatrists International Congress (RCPsych 2023) confirm the importance of SPRAVATO® as a therapeutic option for adults with treatment-resistant major depressive disorder in patients with 2 and >3 prior treatment failures.1 10 July 2023: The Janssen Pharmaceutical Companies of Johnson & Johnson announced further findings from the ESCAPE-TRD study. Data…
Magstim Horizon 3.0 Transcranial Magnetic Stimulation now in UK
Approval by UKCA Empowers UK physicians to advance care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with non-invasive brain stimulation The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for sale in the UK, providing physicians with a proven precision therapy to improve…
New government concussion guidance
New guidelines for recognising and managing concussion in grassroots sports have been published by the Government. Aimed at the general public and those engaging with sport on a non-professional level, ‘If In Doubt, Sit Them Out’ is guidance with a very clear message that if an individual is suspected of having concussion, they must be…
Rozanolixizumab and Zilucoplan Phase 3 Generalised Myasthenia Gravis studies
13 April 2023: UCB, a global biopharmaceutical company, announced that The Lancet Neurology has published data from the Phase 3 MycarinG study evaluating the efficacy and safety of rozanolixizumab in adult patients with acetylcholine receptor autoantibody-positive (AChR-Ab+) or muscle-specific tyrosine kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) and the Phase 3 RAISE study evaluating the…
Upstaza™ gene therapy granted marketing authorisation for AADC deficiency by MHRA
PTC Therapeutics, Inc. announced on 17th November that Upstaza™ (eladocagene exuparvovec) was granted authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Upstaza is the first and only approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18…
First super-resolution image of tiny brain receptor could give scientists a better understanding of Parkinson’s and Alzheimer’s
Academic news from University of Birmingham
Improving management of headache, migraine and chronic pain
News of the Elective Care Transformation Programme
Neurological Alliance Report shows increasing number of neurological cases
News from the Neurological Alliance
